New agents and regimens for diffuse large B cell lymphoma

New agents and regimens for diffuse large B cell lymphoma

Abstract As a widely recognized standard regimen, R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) is able to cure two-thirds patients with diffuse large B cell lymphoma (DLBCL), and the remaining patients suffer from refractory or relapsed disease due to resistance...

Full description

Bibliographic Details
Main Authors: Liang Wang, Lin-rong Li, Ken H. Young
Format: Article
Language:English
Published: BMC 2020-12-01
Series:Journal of Hematology & Oncology
Subjects:
Diffuse large B cell lymphoma
Chimeric antigen receptor T cells
Immunotherapy
Chemoresistance
Novel agents
Genetic classification
Online Access:https://doi.org/10.1186/s13045-020-01011-z

Internet

https://doi.org/10.1186/s13045-020-01011-z

Similar Items